Zhang Financial LLC Has $2.06 Million Stake in Pfizer Inc. (NYSE:PFE)

Zhang Financial LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 4.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 71,535 shares of the biopharmaceutical company’s stock after selling 3,648 shares during the period. Zhang Financial LLC’s holdings in Pfizer were worth $2,059,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. RB Capital Management LLC grew its stake in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. grew its stake in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank grew its stake in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the last quarter. Ergoteles LLC grew its stake in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on PFE shares. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Up 1.9 %

PFE stock traded up $0.49 during midday trading on Friday, hitting $25.88. The company’s stock had a trading volume of 21,376,043 shares, compared to its average volume of 42,192,488. The stock has a market capitalization of $146.55 billion, a P/E ratio of 71.67, a PEG ratio of 1.15 and a beta of 0.61. The company’s fifty day moving average price is $27.14 and its 200 day moving average price is $28.74. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.